It is a pharma public limited company based in New Delhi, Delhi, India, established in 2017.
2017 | New Delhi, Delhi, India | ActiveDr Smithkline Laboratories (India) Limited, a active public limited company, was established on 03 February 2017 in New Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24304DL2017PLC311392. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹1.00 M.
It upholds a compliant status. Its leadership includes Satya Narain Bhutani (Director), Vaibhav Bhutani (Director), Sarish Bhutani (Director). Its latest AGM occurred on 30 September 2023, with the balance sheet filed on 31 March 2023. It is based at Plot No.83, Vishwas Nagar, Shahdara, Near Sahdev Gali, New Delhi, Delhi, 110032.
U24304DL2017PLC311392
311392
03 February 2017
₹1.00 M
₹1.00 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Dr Smithkline Laboratories (India) Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Satya Narain Bhutani | Director | 03 Feb 2017 | Current |
| Vaibhav Bhutani | Director | 03 Feb 2017 | Current |
| Sarish Bhutani | Director | 03 Feb 2017 | Current |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Dr Smithkline Laboratories (India) Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 200.15% decrease in profit. The company's net worth dipped by a decrease of 2.92%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2022, Dr Smithkline Laboratories (India) had a promoter holding of 96.00% and a public holding of 4.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Dr Smithkline Laboratories (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Dr Smithkline Laboratories (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr Smithkline Laboratories (India)'s trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Dr Smithkline Laboratories (India) Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records. was documented.
Dr Smithkline Laboratories (India) Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Delhi. was recorded as a recent event.
Progress on Satya Narain Bhutani was appointed as a Director was appointed as a Director on 03 Feb 2017 & has been associated with this company since 8 years 9 months . was documented.
The activity Vaibhav Bhutani was appointed as a Director was appointed as a Director on 03 Feb 2017 & has been associated with this company since 8 years 9 months . was completed.
Sarish Bhutani was appointed as a Director was appointed as a Director on 03 Feb 2017 & has been associated with this company since 8 years 9 months . was recorded as a recent event.
The activity Dr Smithkline Laboratories (India) Limited was registered on 03 Feb 2017 with Roc Delhi & aged 8 years 9 months as per MCA records. was completed.
The CIN of Dr Smithkline Laboratories (India) Limited is U24304DL2017PLC311392.
Dr Smithkline Laboratories (India) Limited is headquartered at Plot No.83, Vishwas Nagar, Shahdara, Near Sahdev Gali, New Delhi, Delhi, 110032.
Dr Smithkline Laboratories (India) Limited was incorporated on 03 February 2017.
The current directors of Dr Smithkline Laboratories (India) Limited are
The primary industry of Dr Smithkline Laboratories (India) Limited is Manufacturing.
Dr Smithkline Laboratories (India) Limited is unlisted.
The authorized capital of Dr Smithkline Laboratories (India) Limited is ₹1.00 M, and the paid-up capital is ₹1.00 M.
The compliance status of Dr Smithkline Laboratories (India) Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX